ASA EFFECTS ON ANTIHYPERTENSIVE EFFICACIES OF ENALAPRIL AND LOSARTAN

ASA 对依那普利和氯沙坦抗高血压疗效的影响

• 批准号: 6274509
• 负责人: SARAH A SPINLER
• 金额: $ 2.5万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-04-15 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6274509
• 关键词: antihypertensive agents; aspirin; blood chemistry; blood pressure; cardiovascular disorder chemotherapy; cardiovascular disorder diagnosis; chemosensitizing agent; clinical research; clinical trials; combination chemotherapy; drug interactions; drug screening /evaluation; enalapril; human subject; human therapy evaluation; hypertension; urinalysis

This research is designed to study the effects of 81 mg and 325 mg of aspirin (ASA) on the individual abilities of enalapril and losartan to lower blood pressure. A secondary objective is to characterize any observed interaction between ASA and losartan or ASA and enalapril by measuring urinary prostanoid concentrations. The null hypothesis is that there is no difference in blood pressure when a low dose or average dose of ASA is added to a monotherapy regimen of either enalapril or losartan. A total of 18 subjects will be recruited, 9 each taking enalapril or losartan. The study involves a 3,2 week treatment periods with either ASA 81 mg, ASA 324 mg or placebo each separated by 2 week washout periods. Sitting BP will be collected via cuff manometry and 12-hour urine collections will be completed and analyzed for PGE2, PGE-M, 6-keto-PGF1alpha, 2,3 dinor-PGI-M, TXB2 and TX-M. Plasma norepinephrine concentrations will also be collected. Urine and plasma analyses and comparisons will only be performed if there is a statistical difference observed in blood pressure between the placebo and ASA-treatment periods.

本研究旨在研究81 mg和325 mg的 阿司匹林（阿萨）对依那普利和氯沙坦个体能力的影响， 降低血压 第二个目标是描述任何 观察到阿萨与氯沙坦或阿萨与依那普利之间的相互作用， 测量尿前列腺素浓度。 零假设 当低剂量或平均剂量时， 在依那普利或依那普利的单药治疗方案中添加一剂阿萨， 氯沙坦。 共招募18名受试者，每名受试者9名， 依那普利或氯沙坦。 这项研究涉及3，2周 治疗 阿萨81 mg、阿萨324 mg或安慰剂治疗期，间隔为 2周洗脱期。 将通过袖带测压法收集坐位BP 完成12小时尿液采集并分析PGE 2， PGE-M、6-keto-PGF1 α、2，3-dinor-PGI-M、TXB2和TX-M。 血浆 还将收集去甲肾上腺素浓度。 尿液和血浆 分析和比较将仅在以下情况下进行： 在安慰剂组之间观察到的血压统计学差异 和ASA治疗期。